What Connected Care ROI Actually Measures
Connected care ROI is the measurable financial return created by connecting patient data, clinical workflows, and communication channels so that the right information reaches the right person at the right time. For payers and provider operators, the calculation should include avoided medical utilization, better resource allocation, lower administrative expense, improved throughput, and better chronic-disease outcomes. It should not rely only on patient engagement, satisfaction, or the number of remote-monitoring devices deployed. Those measures may describe adoption, but they do not prove that the program generated more value than it cost.
Also worth reading: How Do B2B Healthcare Cost-Containment Platforms Work for Payers and Providers in 2026? · What Are the Best Prior Authorization Benchmarks for Payers and Providers in 2026? · How Should Payers and Providers Test CMS-0057-F Readiness After the July 2024 Deadline?
The most defensible ROI equation is (measured financial benefits - total program costs) / total program costs. Financial benefits can include fewer avoidable emergency-department visits, reduced readmissions, lower total cost of care for selected populations, fewer duplicate tests, shorter staffing time per discharge, and improved contribution margin from more appropriate bed placement. Costs include technology licenses, devices, implementation, clinical labor, training, security, integration, analytics, and the time employees spend participating in workflows that previously did not exist. Benefits and costs should use the same measurement period, population, and accounting basis.
A useful target is a positive 12-month benefit-cost ratio, meaning benefits at least equal costs, followed by an ROI above 0%. Many organizations set a higher internal hurdle, often 20% or more, because connected-care programs carry uncertainty and may require renewal or replacement costs. A vendor claiming a “400% ROI,” as described in a July 2025 Forbes article about ManyChat chatbots in other commercial settings, should not be transferred automatically to healthcare. Healthcare returns depend on clinical causality, population selection, reimbursement, data quality, and whether savings are actually retained rather than merely observed in claims data.
How to Build a Credible ROI Model
Begin by defining the decision the connected-care program is intended to improve. If the goal is to reduce 30-day hospital readmissions for patients with heart failure, the model should include enrollment criteria, the intervention period, the comparison population, readmission definitions, attributable savings, and implementation costs. A broad goal such as “improving care coordination” is not measurable enough for an investment decision. Each financial claim should be connected to an operational metric, such as fewer repeated laboratory orders, fewer nurse follow-up calls, or shorter length of stay.
Next, establish a credible baseline. Organizations commonly use claims, encounter data, staffing schedules, bed-management records, referral logs, and prior quality-improvement results. Baselines should cover at least 12 months when seasonal variation matters and should be risk-adjusted for age, diagnoses, prior utilization, acuity, and social needs. For a chronic-disease program, a randomized or matched-control design is stronger than comparing participants with the whole population. If randomization is impractical, difference-in-differences can compare the change among participating patients with the contemporaneous change among a similar non-participating group.
The model should separate gross savings from realized savings. Suppose a program reduces 100 emergency-department visits by $1,500 each, producing $150,000 in gross avoided utilization. If the payer shares only $300 of each saving, the payer’s attributable benefit is $30,000, not $150,000. Provider revenue may also change differently: fewer admissions can free a bed but reduce fee-for-service revenue, while a value-based contract may reward the reduced total cost of care. For that reason, ROI is not identical to savings, cash released, contribution margin, or improvement in a quality score.
| Feature | Simple ROI model | Risk-adjusted ROI model | Financial-only model |
|---|---|---|---|
| Best use | Early pilot screening | Enterprise clinical program evaluation | Administrative efficiency decisions |
| Comparison | Before versus after | Matched controls or staged rollout | Baseline workload versus current workload |
| Time horizon | Usually 3-12 months | 6-24 months | One budget cycle |
| Main strength | Fast and inexpensive | Better causal credibility | Easy to connect to budgets |
| Main weakness | May credit unrelated trends | Requires data and analytic capacity | Can miss clinical and long-term value |
| Typical evidence threshold | Benefits greater than costs | Positive net benefit with confidence intervals | Time savings greater than license and labor cost |
Which Financial and Operational Benefits to Count
Connected care commonly combines remote monitoring, patient messaging, care-team dashboards, referral management, smart-room technology, and data exchange. Baxter’s discussion of measuring healthcare ROI emphasizes that connected-care value should be tied to outcomes and economics rather than adoption alone. Salesforce’s MedTech and Agentforce material similarly frames technology returns around process improvement and measurable business results. These sources are useful for measurement principles, but their examples should be treated as vendor or publisher claims until an organization validates the economics in its own environment.
For chronic conditions, plausible benefit categories include fewer avoidable admissions, shorter length of stay, lower readmission rates, improved medication adherence, and reduced duplicate services. For hospital operations, benefits may include lower call-handling time, faster discharge communication, fewer patient-transport delays, improved room utilization, and less staff time spent locating information. For payers, the primary measure may be lower medical expense for attributed members, while operational benefits include faster prior authorization, fewer manual chart reviews, and improved medical-necessity review. DaVita’s 2025 Healthcare IT News report on using connected data in kidney care illustrates the practical appeal of linking clinical and operational information, but it does not establish a universal savings rate.
Targets should be selected from the organization’s own data. A hospital might set a threshold of reducing 30-day heart-failure readmissions from 18% to 15%, lowering average discharge-processing time by 20%, or saving 10 full-time-equivalent hours per month. A payer might require total cost of care per member per month to decline by at least $30 while maintaining quality. These are examples of targets, not industry benchmarks, and they should be reset after a baseline is measured. Numeric targets are most useful when paired with a named owner, a review date, and a rule for deciding whether the intervention continues.
Patient and caregiver outcomes remain important even when they do not convert directly into first-year cash. Reduced distress, better access to a clinician, fewer language barriers, and improved ability to manage a condition can affect retention, service utilization, and workforce performance. However, these outcomes should not be assigned invented dollar values. Organizations should use validated measures, document the evidence for any monetization, and keep clinical benefit separate from financial return when confidence is limited. A program with strong patient value but negative first-year ROI may still merit investment if a payer-provider contract or longer time horizon supports later benefits.
Practical Steps for a 90-Day Evaluation
A practical evaluation can begin with a 30-day design phase. Select one population and one workflow, such as post-discharge heart-failure management or high-risk surgical discharge. Document the current process, baseline spending, utilization, staffing effort, quality outcomes, and known data gaps. Define what counts as a participating patient, when enrollment begins, and how long follow-up continues. Assign clinical, operational, financial, privacy, and technology owners so that clinical savings are not claimed solely by a software vendor.
Days 31-60 should be used to configure measurement and conduct a limited pilot. Integrate claims, EHR, scheduling, and relevant care-management data where possible, while preserving the ability to reconcile results against source records. Establish privacy controls for patient-level data, role-based access, consent requirements where applicable, and audit trails. Track process measures weekly and financial measures monthly, because utilization changes can lag behind implementation. Record implementation effort separately; otherwise, an apparently efficient program may merely exclude the analysts and trainers whose labor made it work.
Days 61-90 should provide a preliminary read on whether the program deserves a longer trial. Review enrollment, engagement, data completeness, workflow adherence, safety events, utilization, staffing time, and costs. Compare the pilot with a credible control or historical benchmark and calculate confidence intervals where sample size permits. A pilot may demonstrate feasibility without proving savings, especially if the number of participants is small or follow-up is under six months. In that case, the correct conclusion may be “continue for validation,” not “scale immediately.”
Before scaling, require an operating model. Identify who monitors alerts, who responds after hours, how technology failures are handled, and whether downstream capacity exists. For example, remote monitoring can generate alerts that increase workload if no clinician has time to act on them. A well-designed workflow should define alert thresholds, escalation rules, coverage schedules, and documentation requirements. It should also include a termination rule, such as stopping a pathway if incremental cost per event avoided remains above the organization’s negotiated threshold for two consecutive review periods.
Comparing Connected-Care Alternatives
Connected care is an operating model, not a single product. Organizations can buy an integrated platform, combine point solutions, use a payer-provider service, or build a program around existing EHR and communication tools. The lowest purchase price may produce the highest total cost when integration, clinical labor, and training are omitted. Conversely, a more expensive platform can be rational if it reduces duplicate data entry and supplies reliable outcome reporting, but the vendor must demonstrate that those benefits are real for the customer’s environment.
| Decision factor | Integrated connected-care platform | Point solutions | Internal workflow redesign |
|---|---|---|---|
| Upfront cost | Medium to high | Low to medium | Medium because of staff time |
| Integration burden | Usually lower | Often higher | Depends on internal skills |
| Time to launch | Commonly weeks to months | Commonly months | Can be slow |
| Data consistency | Better when product is well implemented | Requires careful reconciliation | Depends on governance |
| Main ROI risk | Vendor pricing and weak adoption | Fragmentation and duplicate work | Internal capacity and sustainability |
| Best suited to | Standardized multi-site programs | Narrow use cases with existing tools | Organizations with strong clinical operations |
Outsourcing to a care-management vendor can improve speed but may obscure ROI if the contract measures only activity. Pricing may be per member per month, per enrolled patient, per completed touchpoint, per discharge, or a blended fee. These models reward different behaviors and can create incentives for unnecessary contacts or enrollment of low-risk members. A useful contract should define eligible populations, data ownership, response-time standards, quality measures, shared-savings treatment, audit rights, termination provisions, and the calculation of net performance payment.
Common Mistakes That Inflate or Hide ROI
The most common mistake is counting avoided costs that the organization does not retain. Clinical savings may accrue to a payer while a provider bears implementation costs, or a hospital may free capacity but remain in fee-for-service and lose revenue. The second mistake is attributing normal improvements to the technology. New staffing, a concurrent quality initiative, seasonal changes, or coding changes can all affect readmissions and spending. A third error is excluding ongoing labor, particularly clinician time spent reviewing alerts and completing documentation.
Organizations also confuse activity with value. A dashboard that is viewed 1,000 times is not necessarily improving decisions, and a patient who receives six messages may not become healthier than a patient who receives two effective messages. Engagement thresholds can still be useful operationally, but they should be connected to outcomes. For example, a program might use at least 70% device transmission as an operational target while treating a statistically credible reduction in events as the financial test.
Sample-size errors are another problem. A 3% improvement based on 20 patients may be unstable, while a 3% improvement across several thousand matched members may be meaningful. Always report denominator, period, missing-data rate, confidence interval, and whether the result is clinically or financially material. Avoid applying results from one disease, country, reimbursement system, or provider network without adjustment. Healthcare ROI is local: a program’s return depends on baseline cost, population risk, labor supply, contract incentives, and the organization’s ability to act on the data.
Claims projections should also be labeled as projections. A model may estimate $2 million in savings, but only reconciled, realized savings after completion should be reported as achieved financial return. Vendors may provide a calculator or benchmark, but those estimates are useful for screening and negotiation only when their assumptions are visible. hcco.app should present connected-care ROI as a disciplined measurement practice, not as a promise that every connected-care investment produces a particular return.
When to Act, Pause, or Scale
Act decisively when a problem is expensive, measurable, and addressable by a workflow change. Strong early signals include high readmission rates, repeated avoidable testing, delayed discharge communication, staffing bottlenecks, or fragmented referral information. A limited pilot is usually preferable to a broad rollout because it tests whether the intervention changes behavior without creating excessive workload or safety risk. The initial threshold need not be a positive enterprise ROI; it can be a credible path to validated benefit within six to twelve months.
Pause or redesign when utilization declines are visible but staffing effort rises faster than benefits, data feeds are unreliable, or no team can act on generated alerts. Also pause if the organization lacks a control group or baseline, if the vendor cannot provide auditable data, or if contractual savings cannot be retained. If benefits are delayed beyond the budget cycle, quantify the expected payback period and secure the funding needed to reach it. A program with a 24-month payback can still be reasonable for infrastructure or safety, but it should not be represented as a six-month savings project.
Scale when the program has demonstrated clinical safety, operational acceptance, reliable data, and a positive net result under conservative assumptions. Scale in stages by site, service line, or member cohort, preserving a comparison group where feasible. Establish quarterly reviews and annual recalibration because staffing costs, reimbursement, patient mix, and vendor pricing can change. As of October 1, 2026, organizations should also verify current privacy, security, interoperability, and payment policies with their compliance and contracting teams rather than relying on a generic market assumption.
A Decision Rule That Executives Can Use
Executives can approve a connected-care investment when five conditions are met: the target problem has a documented baseline, the intervention has a measurable owner and timeline, total costs include implementation and ongoing labor, benefits use a risk-aware comparison, and the organization has a plan to act on results. A useful approval memo can show first-year base-case ROI, conservative-case ROI, 24-month cumulative cash flow, quality safeguards, and the threshold for stopping or expanding. It should distinguish payer savings, provider savings, patient benefit, and enterprise-level return.
For example, a program costing $500,000 and producing $750,000 in retained, risk-adjusted benefits has a 50% first-year ROI. If only $300,000 is retained because savings are shared and benefits are delayed, ROI is -40% despite $450,000 in gross clinical value. Neither conclusion is automatically right: the first may overstate realized value, while the second may omit valuable patient outcomes or later contract payments. The decision depends on who pays, who saves, when savings occur, and whether the program meets clinical obligations.
The practical message for hcco.app is straightforward: connected-care ROI is not a technology score. It is an evidence-based comparison between attributable benefits and fully loaded costs, measured in a defined population and period. Payers and providers that make that comparison can make stronger procurement decisions, explain performance to finance leaders, and avoid scaling programs that merely look modern. The strongest 2026 organizations are not those with the most dashboards or devices; they are those that know which costs changed, which patients benefited, which results were independently credible, and whether the next dollar should be invested.